Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines

[1]  Dirk Schadendorf,et al.  Mapping heterogeneity in patient-derived melanoma cultures by single-cell RNA-seq , 2016, Oncotarget.

[2]  J. Sosman,et al.  Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma , 2016, Current Oncology Reports.

[3]  Steven J. M. Jones,et al.  Genomic Classification of Cutaneous Melanoma , 2015, Cell.

[4]  A. Rust,et al.  BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model , 2015, Proceedings of the National Academy of Sciences.

[5]  K. McMasters,et al.  Adenovirus-mediated FKHRL1/TM sensitizes melanoma cells to apoptosis induced by temozolomide. , 2014, Human gene therapy. Clinical development.

[6]  Samra Turajlic,et al.  BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells by Reactivating MEK and ERK Signaling , 2014, Science Signaling.

[7]  M. Millward,et al.  Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression , 2013, The British journal of dermatology.

[8]  A. Hauschild,et al.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.

[9]  Jane Fridlyand,et al.  Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors , 2012, Nature.

[10]  T. Golub,et al.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.

[11]  J. Annereau,et al.  Melanoma Chemotherapy Leads to the Selection of ABCB5-Expressing Cells , 2012, PloS one.

[12]  M. McCarter,et al.  Side Population Cells from Human Melanoma Tumors Reveal Diverse Mechanisms for Chemoresistance , 2012, The Journal of investigative dermatology.

[13]  R. Rees,et al.  The Helicase HAGE Expressed by Malignant Melanoma-Initiating Cells Is Required for Tumor Cell Proliferation in Vivo* , 2012, The Journal of Biological Chemistry.

[14]  S. Nelson,et al.  Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance , 2012, Nature Communications.

[15]  Tom Misteli,et al.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.

[16]  Brian J. Wilson,et al.  ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients. , 2011, Cancer research.

[17]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[18]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[19]  Damien Kee,et al.  Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.

[20]  J. Kim,et al.  p-Glycoprotein ABCB5 and YB-1 expression plays a role in increased heterogeneity of breast cancer cells: correlations with cell fusion and doxorubicin resistance , 2010, BMC Cancer.

[21]  F. García-Sierra,et al.  ATP-binding cassette transporter ABCB5 gene is expressed with variability in malignant melanoma. , 2010, Actas dermo-sifiliograficas.

[22]  M. Gottesman,et al.  Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma , 2009, Pigment cell & melanoma research.

[23]  W. Sellers,et al.  MEK1 mutations confer resistance to MEK and B-RAF inhibition , 2009, Proceedings of the National Academy of Sciences.

[24]  M. Gottesman,et al.  Influence of melanosome dynamics on melanoma drug sensitivity. , 2009, Journal of the National Cancer Institute.

[25]  R. DePinho,et al.  BRafV600E cooperates with Pten silencing to elicit metastatic melanoma , 2009, Nature Genetics.

[26]  A. Elliott,et al.  ABCB8 Mediates Doxorubicin Resistance in Melanoma Cells by Protecting the Mitochondrial Genome , 2009, Molecular Cancer Research.

[27]  M. Gottesman,et al.  Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[28]  W. Sadee,et al.  ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. , 2005, Cancer research.

[29]  William C Reinhold,et al.  Membrane Transporters and Channels , 2004, Cancer Research.

[30]  M. Sayegh,et al.  Regulation of Progenitor Cell Fusion by ABCB5 P-glycoprotein, a Novel Human ATP-binding Cassette Transporter* , 2003, Journal of Biological Chemistry.

[31]  Michael E. Egger,et al.  Sentinel Lymph Node Genes to Predict Prognosis in Node-Positive Melanoma Patients , 2016, Annals of Surgical Oncology.